Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iTILT: HSPC Infusion for Immune Tolerance in Liver Transplant Recipients
NCT07269041Phase 2Recruiting
- Sponsor
- University of California, Los Angeles
- Start
- Feb 2026
- Primary completion
- Jan 2029
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of donor hematopoietic stem and progenitor cell infusion (UCLA) in liver transplantation, sponsored by University of California, Los Angeles. Started Feb 2026; status: recruiting.
02
Drugs
donor hematopoietic stem and progenitor cell infusion (UCLA)
03
Conditions
liver transplantation
Beyond the preview
Go deeper on NCT07269041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07269041.